<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2536">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04395716</url>
  </required_header>
  <id_info>
    <org_study_id>PRG-048</org_study_id>
    <nct_id>NCT04395716</nct_id>
  </id_info>
  <brief_title>A Study of ResCure™ to Treat COVID-19 Infection</brief_title>
  <official_title>A Phase I Study of ResCure™ to Treat COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProgenaBiome</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rinati Skin, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ProgenaBiome</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I open-label interventional study which will test the efficacy of ResCure™ in
      the treatment of patients with COVID-19 infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this Phase I open-label interventional study we will test the efficacy of ResCure™ in the
      treatment of patients with COVID-19 infection. Patients being treated will have severe
      respiratory symptoms that are at or near requiring the patient be placed on a ventilator.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of recovery of mild or moderate COVID-19 in patients using ResCure™</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Number of days from COVID-19 diagnosis to recovery via RT-PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction or progression of symptomatic days</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Reduction and/or progression of symptomatic days, reduction of symptom severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the safety of ResCure™ via pulse</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Pulse from baseline to 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the safety of ResCure™ via oxygen saturation</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Oxygen saturation from baseline to 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the safety of ResCure™ via EKG</measure>
    <time_frame>12 Weeks</time_frame>
    <description>EKG from baseline to 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess Tolerability of ResCure™</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Assess Adverse Events and Serious Adverse Events due to ResCure™</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>COVID</condition>
  <condition>Covid-19</condition>
  <condition>Corona Virus Infection</condition>
  <condition>Sars-CoV2</condition>
  <condition>Coronavirus-19</condition>
  <condition>SARS Pneumonia</condition>
  <condition>SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will be treated with nebullized ResCure™ while hospitalized every 4 to 6 hours, depending on disease severity and ventilator status.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ResCure™</intervention_name>
    <description>Patients will be treated with nebulized ResCure™</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Critically ill patients with SARS from COVID-19 infection on respirators OR

          2. Patients with SARS from COVID-19 infection prior or after being placed on respirator

          3. Male or female patients 18 years of age and older

        Exclusion Criteria:

        1. Patients less than 18 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine Hazan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ProgenaBiome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Hazan, MD</last_name>
    <phone>805-339-0549</phone>
    <email>drsabinehazan@progenabiome.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jordan Daniels, MS</last_name>
    <phone>805-339-0549</phone>
    <email>msjordandaniels@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ProgenaBiome</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>May 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2020</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

